Jintanat Ananworanich, MD, PhD

Jintanat Ananworanich, MD, PhD

The University of Maryland School of Medicine

Professor of Internal Medicine
The University of Amsterdam, The Netherlands
Clinical Professor, Department of Pediatrics
The University of Maryland School of Medicine
Baltimore, Maryland


Committees and Organizations

  • Steering committee member, Pediatric European Network for Treatment of AIDS, Organizing committee of the International Workshop on HIV Pediatrics at the IAS
  • Member of the ACTG and IMPAACT HIV cure committees, member of the amfAR GMT      research advisory group, member of the 2015 IAS Track B committee, member of the Steering Committee of the International Scientific Working Group of the IAS Towards an HIV Cure Initiative, Editor-in-Chief for the Journal of Virus Eradication
  • Member of the scientific committee of the R4P prevention and vaccine meeting

Honors and Awards

  • 1992  Prince of Songkhla Medical School
  • 1999  American Academy of Allergy, Asthma and Immunology Centeon Fellowship Stipend in Clinical and Laboratory Immunology
  • 2015  Her Royal Highness Princess Soamsawali’s Award for contribution to the advancement of HIV care and research in Thailand
  • 2016  Outstanding Alumni Award from Prince of Songkhla Medical School
  • 2016  Outstanding Alumni Award from Prince of Songkhla University
  • as Lancet, AIDS, CID, JID, JAIDS, AVT, PIDJ, JACI, HIV Medicine, Deputy Editor for AIDS Research and Therapy

Education

INSTITUTION AND LOCATION DEGREE

(if applicable)

Completion Date

MM/YYYY

FIELD OF STUDY

 

Prince of Songkhla University, Thailand M.D. 05/1992 Medicine
Prince of Songkhla University, Thailand Resident 08/1993 Pediatrics
University of Chicago, IL Intern 1995 Pediatrics
University of Chicago, IL Resident 1997 Pediatrics
Baylor College of Medicine, Houston, TX Fellow 1999 Allergy and Immunology
Baylor College of Medicine, Houston, TX Fellow 2000 Clinical Laboratory Immunology
University of Amsterdam, The Netherlands Ph.D. 2008 Medicine

Selected Publications

  1. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne U, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, the Staccato Study, the Swiss HIV Cohort Study. (2006). CD4-guided schedule treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato Randomized Trial. The Lancet. 368:459-65. PMID: 16890832
  2. Puthanakit T, Vonthanak S, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U , Kerr SJ,  Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Ngo-Giang-Huong N,  hettra K, Cheunyam T, Suwarnlerk T, Ubolyam S,  Shearer WT, Paul R, Mofenson LM, Fox L, Law MG, Cooper DA, Phanuphak P, Vun MC, Ruxrungtham K, on behalf of the PREDICT Study Group. (2012). Early versus deferred antiretroviral therapy for HIV-infected children older than one year of age: PREDICT – a randomised study. Lancet Infectious Diseases 12(12):933-41. PMCID: PMC3541427
  3. Ananworanich J, Puthanakit T, Suntarattiwong P, Chokephaibulkit K, Kerr SJ, Fromentin R, Bakeman W, Intasan J, Mahanontharit A, Sirivichayakul S, Chomont N on behalf of the HIV-NAT 194 Study Group. (2014). Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS Apr 24;28(7):1015-20. PMID: 24384692
  4. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J (2016). International AIDS Society global scientific strategy: towards an HIV cure 2016.Nat Med. 2016 Jul 11. doi: 10.1038/nm.4108. PMID: 27400264
  5. Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, Estes JD, Sandler NG, Sukhumvittaya S, Marovich M, Jongrakthaitae S, Akapirat S, Fletcher JLK, Kroon E, Dewar R, Trichavaroj R, Chomchey N, Douek DC, O’Connell RJ, Ngauy V, Robb ML, Phanuphak P, Michael NL, Excler JL, JH Kim, de Souza MS, Ananworanich J on behalf of the RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups. (2014). Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-related Immune Activation. PLOS Pathogens Dec 11;10(12):e1004543. PMCID: PMC4263756.
  6. De Souza MS, Phanuphak N, Pinyakorn S, Trichavaroj R, Pattanachaiwit S, Chomchey N, Fletcher JL, Kroon ED, Michael NL, Phanuphak P, Kim JH, Ananworanich J; RV254SEARCH 010 Study Group. (2015). Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS. Apr 24;29(7):793-800. PMID: 25985402
  7. de Souza MS, Pinyakorn S, Akapirat S, Pattanachaiwit S, Fletcher JL, Chomchey N, Kroon ED, Ubolyam S, Michael NL, Robb ML, Phanuphak P, Kim JH, Phanuphak N, Ananworanich J; RV254/SEARCH010 Study Group (2016). Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. Clin Infect Dis. PMID: 27317797
  8. Ananworanich J, Chomont N, Eller LA, Kroon E, Tovanabutra S, Bose M, Nau M, Fletcher JL, Tipsuk S, Vandergeeten C, O’Connell RJ, Pinyakorn S, Michael N, Phanuphak N, Robb ML; RV217 and RV254/SEARCH010 study groups (2016). HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine. Jul 20. pii: S2352-3964(16)30330-9. doi: 10.1016/j.ebiom.2016.07.024. PMID: 27460436
  9. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, Suwanwela NC, Jagodzinski L, Michael N, Spudich S, van Griensven F, de Souza M, Kim J, Ananworanich J on behalf of the RV254/SEARCH 010 Study Group. (2012). Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. Jul 15;206(2):275-82. PMCID: PMC3490695.
  10. Puthanakit T, Ananworanich J, Vonthanak S, Kosaralaksa P, Hansudewechakul R, van der Lugt J, Kerr SJ, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Vibol U, Purksakaew K, Suwanlerk T, Apornpong T, Ratanilok K, Paul R, Mofenson LM, Fox L, Valcour V, Brouwers P, Ruxrungtham K on behalf of the PREDICT Study Group. (2013). Cognitive function and neurodevelopmental outcomes in HIV-infected children older than 1 year of age randomized to early versus deferred antiretroviral therapy: The PREDICT Neurodevelopmental Study. Pediatr Infect Dis J. May;32(5):501-8. PMCID: PMC3664246.
  11. Kallianpur KJ, Valcour VG, Lerdlum S, Busovaca E, Agsalda M, Sithinamsuwan P, Chalermchai T, Fletcher JL, Tipsuk S, Shikuma CM, Shiramizu BT, Ananworanich J. (2014). HIV DNA in CD14+ reservoirs is associated with regional brain atrophy in patients naive to combination antiretroviral therapy. AIDS. Jul 17;28(11):1619-24. PMCID: PMC4170526.
  12. Peluso MJ, Valcour V, Ananworanich J, Sithinamsuwan P, Chalermchai T, Fletcher JLK, Lerdlum S, Chomchey N, Slike B, Sailasuta N, Gisslén M, Zetterberg H, Spudich S on behalf of the RV254/SEARCH 010 and SEARCH 011 Study Teams. (2015). Absence of cerebrospinal fluid signs of neuronal injury before and after immediate antiretroviral therapy in acute HIV infection. J Infect Dis. May 20. pii: jiv296. PMID: 25995196, PMCID: PMC4633761.
  13. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J, on behalf of the HIV-NAT 086 study team.  (2010). HIV-1 drug resistance mutations after failing first line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in children. HIV Med. Oct 1;11(9):565-72. PMID: 20345882
  14. Puthanakit T, Jourdain G, Suntarattiwong P, Chokephaibulkit K, Siangphoe U, Suwanlerk T, Prasitsuebsai W, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Waranawat N, Ananworanich J on behalf of the HIV-NAT 086 study team. (2012). High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther. Jun 18;9(1):20. PMCID: PMC3469338.
  15. Kosalaraksa P, Ananworanich J, Puthanakit T, Pinyakorn S, Lumbiganon P, Chuanjaroen T, Chobkarjing U, Phanuphak P, Pancharoen C, Bunupuradah T. (2013). Long-Term Lopinavir/Ritonavir Monotherapy in HIV-Infected Children. Pediatr Infect Dis J. Apr;32(4):350-3.
  16. Bunupuradah T, Puthanakit T, Fahey P, Kariminia A, Yusoff KN, Khanh TH, Sohn AH, Chokephaibulkit K, Lumbiganon P, Hansudewechakul R , Razali K, Kurniati N, Huy BV, Sudjaritruk T, Kumarasamy N, Fong SM, Saphonn V, Ananworanich J on behalf of TApHOD. (2013). Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children. Antivir Ther. 18(4):591-8. PMCID: PMC3715593.